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Abstract
Sequencing costs currently prohibit the application of single cell mRNA-seq for many biologi-
cal and clinical tasks of interest. Here, we introduce an active learning framework that constructs
compressed gene sets that enable high accuracy classification of cell-types and physiological states
while analyzing a minimal number of gene transcripts. Our active feature selection procedure
constructs gene sets through an iterative cell-type classification task where misclassified cells are
examined at each round to identify maximally informative genes through an ‘active’ support vec-
tor machine (SVM) classifier. Our active SVM procedure automatically identifies gene sets that
enables > 90% cell-type classification accuracy in the Tabula Muris mouse tissue survey as well
as a ∼ 40 gene set that enables classification of multiple myeloma patient samples with > 95%
accuracy. Broadly, the discovery of compact but highly informative gene sets might enable drastic
reductions in sequencing requirements for applications of single-cell mRNA-seq.
Introduction
Single-cell mRNA-seq methods have scaled to allow routine transcriptome-wide profiling of thou-
sands of cells per experimental run. While single cell mRNA-seq approaches provide important
insights into many different biological and biomedical problems, high sequencing costs prohibit
the broad application of single-cell mRNA-seq in many exploratory assays such as drug and genetic
screens as well as in cost sensitive clinical assays. The sequencing bottleneck has led to the de-
velopment of targeted mRNA-seq strategies that reduce sequencing costs by focusing sequencing
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resources on highly informative genes for a given biological question or an analysis [1, 2, 3, 4, 5].
Commercial gene targeting kits, for example, reduce sequencing costs through selective amplifica-
tion of specific transcripts using 1000 gene targeting primers. Such approaches can reduce costs
by 90% by focusing sequencing resources on highly informative transcripts.
Targeted sequencing approaches require computational methods to identify highly informative
genes for specific biological questions, systems, or conditions. A range of computational ap-
proaches including differential gene expression analysis can be applied to identify highly infor-
mative genes. However, current methods for defining target gene sets often require heuristic user-
defined thresholds for gene set selection and are computationally expensive to apply to large single
cell mRNA-seq data sets [6, 7]. As an example computational approaches based upon matrix
factorization (PCA[8], NNMF[9]) are typically applied to complete data sets which becomes pro-
hibitively expensive when data sets scale into the millions of cells.
Here, we introduce a computational method that applies an active learning[10] approach to identify
minimal gene sets for identifying cell-types and transcriptional states in single-cell mRNA-seq.
Our method identifies minimal gene sets for performing a cell-type classification task of interest
through iterative performance of classification followed by active examination of misclassified
cells to discover highly-informative genes. Our method is inspired by Sequential Feature Selection
(SFS)[11], where features (genes) are selected one by one. However, in our method, we approach
sequential feature selection through an active learning strategy with a support vector machine[12]
classifier (‘active SVM’). At each round of iteration, our procedure analyzes only the cells that
classify poorly with the current gene set, and the procedure extends the gene set by identifying
genes within incorrectly classified cells that will maximally shift the classification margin. As the
procedure focuses computational resources on poorly classified cells, the method can be applied
to large data sets and discovers compact sets of genes that can distinguish between cell-types at
high accuracy (∼ 90%) from single-cell transcriptional data. Our active SVM methods, thus,
provides an efficient computational strategy for constructing minimal gene sets that meet user
defined classification goals from large single-cell mRNA-seq data sets.
We apply our active feature selection method to three test cases: a dataset of peripheral blood
mononuclear cells (PBMCs) [13], the Tabula Muris mouse tissue survey[14], and a data set of
multiple myeloma patient PBMCs [15]. We also systematically compare the performance of the
method to six existing conventional feature selection methods, showing that our method outper-
forms other methods in terms of classification accuracy. Gene sets constructed by active SVM are
extremely compact, and, for example, can by applied to efficiently classify human immune cell
types within PMBCs using as few as 15 genes. The gene sets we discover include both classical
markers as well as new genes not previously established as canonical markers. Our approach is
broadly applicable to discovering efficient minimal gene sets for classifying cell types across a
range of single-cell profiling applications.
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Method
We developed a computational framework based on support vector machine (SVM) classifier to
identify minimal gene sets that distinguish a set of cell-states in single-cell data. The procedure
is an ‘active’ formulation of classical Sequential Feature Selection(SFS) [11]. In the conventional
SFS approach, features are selected one-by-one in a greedy fashion to optimize an objective func-
tion. To reduce computational burden, we propose an active feature selection framework here,
where we only use the subset of incorrectly classified cells at current step and then select the new
feature based upon those cells. The active learning strategy enables efficient computation of min-
imal gene sets across large data sets by minimizing the total number of cells and genes that are
analyzed.
In summary, our algorithm is applied to single-cell gene expression data and tasks, as input, gene
expression data and cell-type labels, or alternately, we generate cell-type labels using unsupervised
clustering. Our procedure, then, starts with an empty gene set, an empty cell set and a list of can-
didate genes and cells. The algorithm iteratively selects genes and classifies cells using identified
genes by training a SVM model to classify cell-types. The algorithm identifies cells in the data
set that classify poorly given the current gene set, and uses those cells to select additional genes to
improve classification accuracy on the entire data set.
In single cell gene expression data, we use x(j)i ∈ R to denote the measurement of the j-th gene of
the i-th cell and x(D)i = [x
(j)
i ]j∈D. Here, we assume the classification labels are given and consider
a data-set {xi, yi}i∈{1,...,N} contains N cells with total M genes, where xi = [x(j)i ]j∈{1,...,M} and
yi ∈ ZN are labels. The labels could be binary or multi-class. And we use J and I to refer to the
set of selected genes and cells.
First, to seed the gene list, the algorithm selects c cells at random out of the total set of N cells
and adds them to the cell-set. The parameter c is determined by the user. The algorithm, then,
trains an SVM on the cell set, which defines an SVM margin w that optimally separates cells into
classes that are consistent with labels on this seed set. A gene selection strategy we developed,
max margin rotation, evaluates all candidate genes based on the margin w and one gene with the
highest score is added to the gene set. A second SVM model is, then, learned given the current
gene set, and, we identify cells that classify poorly given the current gene list. Then we sample c
misclassified cells to identify genes that improve classification in the next step of our procedure.
The integrated algorithm is shown in Algorithm 1.
The two novel components of the method are the strategies to evaluate and select genes and cells
in each iteration. Specifically, we identify cells that classify poorly and use misclassified cells to
identify highly informative genes. To select highly informative genes given the misclassified cells,
a range of different strategies can be applied. In the conventional SVM, the procedure would sort
features according to the absolute values of the components of weight w.[16] Here we use a new
strategy we proposed, called Maximum Margin Rotation, which exhibits superior computational
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Figure 1: Description of Active SVM Feature Selection(ASFS). At the n-th step, an n-D SVM using all
already selected genes is trained to select a certain number of misclassified cells, which is the cell selection
step. In gene selection step, the least classifiable cells are taken as the training set. Based on this training set,
N -n (n+1)-D SVMs are trained, where n dimensions are the same selected genes and the last dimension
is one of the previously unselected candidate genes. Then we would obtain N -n weights w′ corresponding
N -n unselected genes as well as N -n margin rotation angle θ between every w′ and the original weight w
of the n-D SVM. The gene with the maximum rotation of margin is selected for the next round.
performance in biological datasets. Based on SVM, we can formalize the specific gene and cell
selection strategies into two defined rules.
Assume the SVM classifier notation of one observation is hw,b(x
(D)
i ) = g(w
Tx
(D)
i + b) for any
i ∈ {1, 2, . . . , N} and D ⊂ {1, 2, . . . ,M} with respect to observation x ∈ R|D|, where w ∈ R|D|
and b ∈ R are parameters (the margin and bias respectively). Here, g(z) = 1 if z ≥ 0, and
g(z) = −1 otherwise. And the loss function is Hinge Loss[17] lossi = max{0, 1− yihw,b(x(D)i )},
where yi ∈ R is the ground truth label of observation xi.
Cell selection: identification of maximally informative cells
For the cell selection strategy, we simply choose cells with largest SVM classification loss. We
identify such cells through analysis of the dual form of the classical SVM classification problem.
According to [18], after solving the primal optimization problem of soft margin SVM, we have the
dual optimization problem with a non-negative Lagrange multipliers αi ∈ R for each inequality
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where C ∈ R is a hyper-parameter we set to control the trade-offs between size of margin and
margin violations when non-separable.
Then we solve the optimal solution α∗ and apply the Karush-Kuhn-Tucker(KKT) dual-complementarity
conditions[19] to obtain the following results where w ∈ R|J | and the intercept term b ∈ R are
optimal
α∗i = 0 ⇒ yi(wTx
(J)
i + b) > 1
α∗i = C ⇒ yi(wTx
(J)
i + b) < 1
0 < α∗i < C ⇒ yi(wTx
(J)
i + b) = 1.
(2)
Therefore, for each cell, the Lagrange multipliers αi indicates whether the cell falls within the
SVM margin defined by the vector w. αi > 0 means yi(wTxi + b) ≤ 1, i.e. cells are on or inside
SVM margin. Hence, we can directly select cells with αi > 0. In practice, normally we only select
cells with αi = C, which means incorrectly classified cells.
Using this mathematical formulation, we were able to develop two different versions of the AFSF
procedure, min-complexity strategy and min-cell strategy, for different purposes. The min-complexity
strategy minimizes the computational complexity of the framework. A certain fixed number of
cells is randomly selected among all misclassified cells each iteration. Therefore, a small number
of cells can be analyzed at each round and typically few cells are used repeatedly. In the min-cell
strategy, the procedure minimizes the total number of unique cells we acquire during the procedure.
Therefore, the misclassified cells already used in previous steps are selected with first priority. In
details, assume we should use c cells for each iteration and there are a + b misclassified cells at
current iteration, where a cells are used at least one time in previous iterations while b cells are
newly selected. If a ≥ c, we should randomly select c cells among these a cells we used before.
If a < c, we should add these a used cells and randomly select c − a cells in b new cells. When
using min-cell strategy, cells tend to be re-used many times and the curve of number of unique
cells we acquired should be convergent along with the number of genes we select. In experiments,
the number of cells for each step, c, is a hyper-parameter set by the user. Typically, the parameter
can be set to a small number using min-complexity strategy as a sufficient number of new cells is
5
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted June 16, 2021. ; https://doi.org/10.1101/2021.06.15.448478doi: bioRxiv preprint 
considered in the procedure. Selecting a small number of cells each round reduces computational
complexity. In the min-cell strategy it can be advantageous to select a larger number of total cells
to guarantee diversity of training cells.
Another consideration is to balance the number of cells sampled of classes to avoid rapidly dimin-
ishing results for small clusters. Therefore, besides randomly sampling misclassified cells of every
classes, we have another cell sampling strategy called ’balanced’ sampling. Specifically, assume
there are Z classes and we should use c cells for each iteration. Assume there are a =
∑Z
z=1 az
misclassified cells at current iteration, where a1 < a2 < . . . < aZ are the number of cells in Z
classes. If a1 ≥ c/Z, we should randomly sample c/Z cells for each cell type. Otherwise, if
a1 < c/Z, we should add all a1 cells. Then if a2 < (c − a1)/(Z − 1), we should add all a2 cells.
This procedure repeats until encountering a class, for example class z0, with sufficient misclassi-
fied cells. Then (c−
∑z0−1
z=1 az)/(Z−z0+1) misclassified cells should be sampled at random from
each rest class.
Gene selection by maximizing margin rotation
To select genes, we analyze the misclassified cells to identify genes that will induce the largest
rotation of the margin, which inspired by the popular active learning method, Expected Model
Change[20]. We quantify rotation of the margin by calculating the twist angle induced in w when
we add a new dimension (gene) to the classifier. Assume J is the set of genes we have selected so
far. Once we add a gene into the |J |-dimensional data space, the parameter w will have one more
dimension. The rotation of margin measures how much w twists after adding the new dimension
compared with weight in the previous iteration.
Specifically, assume J is the set of genes we have selected so far. According to [18], we derive the








Then we pad w with zero to get a |J + 1|-dimensional weight wpadded, whose first |J | dimensions
is w and the |J + 1|-th dimension is zero.
For each candidate gene j, we train a new |J + 1|-dimensional SVM model and have weight
wj ,where j ∈ {1, . . . ,M} \ J . That is to say, for candidate gene j, we solve the dual optimization
problem (4) and find a new optimal multiplier α∗(j). Note that we only use the selected cells here,
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The angle θj between wj and wpadded is the expected angle the margin rotates with corresponding
to the j-th candidate gene. Then the j-th gene with largest angle θj will be selected. We measure
the angle between two vectors using cosine similarity[21]:
ϑj = arccos cosϑj = arccos
〈wj, wpadded〉
‖ wj ‖‖ wpadded ‖
(6)
Therefore, a new gene which maximizes ϑj is selected to maximize the expected model change.
For multi-class classification, the SVM is handled according to a one-vs-rest scheme[22], where a
separate classifier is fit for each class, against all other classes. Margin rotation is represented as
the sum of weight components in each class dimension. Hence with Z classes, we get Z weight
components corresponding to Z one-vs-the-rest classification decision boundaries. Assume the
weight component for class z of previous |J |-dimensional SVM model is w(z). Denote the |J +1|-
dimensional weight after zero-padding of w(z) as w(z)padded and the new |J + 1|-dimensional weight
component of class z with j-th gene as w(z)j , where z ∈ 1, . . . , Z. Then we have:
ϑ
(z)

















The computational complexity of the complete procedure mainly depends on the training of SVM.
The standard computational complexity of SVM can be as small as O(MN2).[23] Assume that
we plan to select k ∈ N genes in total and use c ∈ N poorly classified cells at each step,
where k  M and c  N are constants. The computational complexity of ASFS should be
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O(
∑k
i=1 (i ·N2 + (M + 1− i) · i · c2)) ∼ O(N2 +M). But in practice, we implement ASFS us-
ing the linear SVM library LIBLINEAR[24], whose computational complexity isO(MN). There-
fore, the corresponding complexity of ASFS is O(M + N). This is a significant improvement in
marker gene selection methods.
Algorithm 1: Active Linear SVM Gene Selection
Input: c, k ∈ N, J = ∅
Output: J
Randomly select c cells I ⊂ {1, . . . , N}, |I| = c
Train a 1-D SVM model on training set I for each candidate gene: {h(j)w,b}j∈{1,...,M}
lossj =
∑





Select one gene j0 ∈ {1, . . . ,M} with lowest lossj
J = J ∪ {j0}
repeat
Optimize (1) and get optimal solution {α∗i }Ni=1








wpadded = [w, 0]








ϑj = arccos cosϑj = arccos
<wj ,wpadded>
‖wj‖‖wpadded‖
Select one gene j∗ ∈ {1, . . . ,M} \ J with largest ϑj
J = J ∪ {j∗}
until |J | ≥ k
Results
We test ASFS method on three biology datasets: a dataset of peripheral blood mononuclear cells
(PBMCs) [13], the Tabula Muris dataset[14], and MM datasets [15]. We test with both min-
cell strategy and min-complexity strategy introduced in Cell Selection part. The figures of Min-
complexity strategy contain both results that balance the number of cells for every classes or not.
The results for both strategies contain four parts: 1) We show the classification accuracy of test
set along with the number of genes we select and compare the performance to several widely-used
feature selection methods, including passive SVM, conventional SVM, correlation coefficient[25],
mutual information[26], Chi-square[27], feature importance by decision tree[28], and randomly
sample genes, showing that ASFS performs best. All of the comparison methods select genes one
by one. At each iteration, they select a new gene with largest score in terms of corresponding
evaluation functions and use the same number of cells as our method. But they randomly sample
cells at each iteration without active learning approaches. Here the method called passive SVM
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chooses genes with the max margin rotation strategy we proposed. Conventional SVM also called
naive SVM selects the gene with largest weight component, which is the most popular SVM feature
selection method. 2) In each case, we provide the plots of total number of unique cells we used
vs. the number of genes during the procedure, which helps to understand the differences and
advantages of min-cell and min-complexity strategies. 3) To indicate the cell type clusters extracted
with the gene set ASFS got, We added the t-SNE projection computed using genes we select as
well as using the entire original filtered gene expression matrix for comparison. 4) We choose
40 genes that provide interesting biological information in these tasks and show their t-SNE plots
highlighting gene expression values using original t-SNE coordinates.
Active feature selection on human PBMC data
To test the performance of the method, we applied our active feature selection method to extract
minimal classifying gene sets for human PBMCs. Specifically, we applied the method to a data
set from [13] that contains 10194 cells profiled via single-cell transcriptional profiling. We used
Louvain clustering[29] to identify T-cells, activated T/NK cells, B-cells, and Monocytes (Figure
2A).
Our active SVM feature selection(ASFS) strategy iteratively selects cells and constructs a gene
list while calculating the classification accuracy on the multi-task SVM classification task. On
the PBMC data, the procedure constructs gene sets of increasing size that can reproduce cell type
clusters (Figure 2B) and classify the 5 major cell-types at greater than 85% accuracy with as few as
15 genes (Figure 2C). On this classification task, aSVM outperforms than other methods including
conventional Sequential Feature Selection, conventional SVM, correlation coefficient [25], mutual
information[26], Chi-square[27], and feature importance by decision tree[28].
A key benefit of the active learning strategy is that a relatively small fraction of the data set is
analyzed, so that the procedure can generate these gene sets while only computing across 200-300
cells (Figure 2D). At each iteration, a set number of misclassified cells (n = 100) are selected
but the total number of cells used does not increase in increments of 100, since some cells are
repeatedly misclassified and are thus repeatedly used for each iteration.
In addition to enabling classification of the cell-types in the data set, the ASFS gene sets provide
a low-dimensional space in which to analyze the data. When we reduced our analysis to consider
only the top 100 genes selected by the ASFS algorithm, we can generate a low-dimensional rep-
resentations of the cell population (t-SNE) that preserve important structural features of the data
including the distinct cell-type clusters [Figure 2B].
The procedure generates gene sets that contain known and novel markers, each plotted individually
in a t-SNE grid [Figure 2E]. For instance, MS4A1 and CD79 are well-established B-cell markers,
and IL7R and CD3G are well-established T-cell markers. However, we also find interesting genes
which are not commonly used as markers, but whose expression is cell-type specific. For instance,
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(c) Original t-SNE(b) The Number of All Acquired Cells
(e) t-SNE of Some Single Selected Genes
(a) Classification Accuracy (d) t-SNE with Selected Genes
A.   Min-cell Strategy
B.   Min-complexity Strategy
Figure 2: Gene selection experiment results of cell type classification on PBMC dataset. Figure A shows
the results up to 100 selected genes using Min-cell strategy with 100 cells are selected at each iteration.
Figure B shows 100 selected genes using Min-complexity strategy using 20 cells each iteration. The subplots
contain: classification accuracy vs. gene set size using min-cell strategy (a) and min-complexity strategy
(f); the total number of unique cells used vs. gene set size with min-cell strategy (b) and min-complexity
strategy (g); the t-SNE plots of entire filtered dataset (c), gene set selected by Min-cell strategy (d), and gene
set selected by Min-complexity strategy with randomly sampling (h) and ’balanced’ sampling (i); t-SNE
of gene expression values for 40 interesting genes selected with min-cell strategy (e) and min-complexity
strategy (j).
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we find highly monocyte-specific expression of FPR1, which encodes N-formylpeptide receptor,
which was recently discovered to be the receptor for plague effector proteins [30]. We also find
T-cell/NK-cell specific expression of a long noncoding RNA, LINC00861, whose function is un-
known but has been correlated with better patient outcome in lung adenocarcinoma [31]. Identified
marker genes generally provide high-specificity for individual cell types, but some mark multiple
cell types (i.e. MARCH1, which marks Monocytes and B-cells).
Identifying optimal gene sets for cell-type classification in Tabula Muris tissue
survey
To test the performance of our active SVM feature selection(ASFS) method at larger-scale, we
applied it to a dataset that includes a large number of unique cell types: the Tabula Muris mouse
tissue survey [14]. We used droplet-based scRNA-sequencing data from Tabula Muris, which
contains 55,656 single cells across 58 annotated cell types, and 12 major tissues. In our assessment,
we used the supplied cell type labels, agnostic of tissue type. Thus, cells labeled ’macrophage’
from the Spleen are considered as belonging to the same class as cells labeled ’macrophage’ from
the Mammary Gland.
Even with a large number of cell types, our active SVM feature selection(ASFS) method can
construct gene sets that achieve high accuracy (> 90%), compared to other methods (Fig 3a). To
construct a gene set of size n=500, ASFS used fewer than 800 unique cells (Fig 3b), which works
out to an average of ∼ 14 cells/cell type. Just as with the PBMC data, we show we recreate
the clustering patterns from the original data (Fig 3c) when analyzing the cells within the low-
dimensional t-SNE space spanned by the selected 500 genes (Fig 3d).
Our approach allows us to construct an informative set of marker genes for identifying mouse cell
types across disparate tissues. Even when computing across a large number of cell types, we can
identify highly cell type specific genes, such as CD3D, a well-established T-cell marker, or TRF
(transferrin), which is known to be selectively secreted by hepatocytes[32], or LGALS7 (galectin-
7), which is known to be specific for basal and differentiated cells of stratified epithelium [33].
However, given the functional overlap between different cell types, the informative genes within
our set include many that mark multiple cell types. For instance, we see that H2-EB1[34], a pro-
tein important in antigen presentation, expressed in both B-cells and Macrophages, both of which
are considered professional antigen presenting cells (APCs). Our analysis also identifies new cell
type-specificity for relatively unknown genes, such as granulocyte-, and hepatocyte- specific ex-
pression of 1100001G20RIK (also known as Wdnm-like adipokine), which had previously only
been associated with adipocytes [35].
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(b) The Number of All Acquired Cells (c) Original t-SNE
(e) t-SNE of Some Single Selected Genes
(a) Classification Accuracy (d) t-SNE with Selected Genes
A.   Min-cell Strategy
B.   Min-complexity Strategy
Figure 3: Identification of minimal gene set for cell type classification in Tabula Muris mouse tissue
survey Figure A shows classification results of 500 genes selected using Min-cell strategy with 200 cells
per iteration. Figure B shows 150 genes selected by min-complexity strategy using 20 cells each iteration.
The results are shown as Figure 2 in accuracy plot, t-SNE, etc.
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Minimal gene sets for classification of disease state in peripheral blood cells
from multiple myeloma patient samples
Having demonstrated the method on identifying cell-type specific markers at both small- and large-
scale, we next turned to applying ASFS to discovering disease-specific markers. We used single-
cell data from peripheral blood immune cells collected from both healthy donors and patients who
have been diagnosed with multiple myeloma [15]. Multiple myeloma (MM) is an incurable cancer
of plasma cells, known as myeloma cells, that overproliferate in the bone marrow. Although the
myeloma cells are typically the target of analysis because they are the causative agent of disease,
the peripherally circulating immune cells also contain signatures of disease. Known signatures in
the peripheral blood include a depleted B-cell population [36, 37], an increased myeloid-derived
suppressor cell count [38], as well as T-cell immunosenescence [39, 37].
In our analysis, we sought to further define transcriptional markers that distinguish healthy periph-
eral immune cells from the cells of MM patients. This dataset contains immune cells from two
healthy donors as well as four MM donors. We performed feature selection using heterogeneous
populations of cells labeled only by disease state. We compared the classification accuracy for the
ASFS method versus other methods (Fig 4a). We found that the ASFS reached high accuracy in
a limited number of steps and consistently outperformed other methods. We also ran the ASFS
method with two cell sampling strategies, randomly sampling, and ’balanced’ sampling, in which
equal numbers of cells from each cell type are sampled to correct for artifacts due to different cell
type proportions between samples. We noted that although the balanced approach (orange line)
gave higher classification accuracy at early iterations, these differences are no longer apparent
after selecting 20 genes.
A t-SNE projection of the original dataset shows completely non-overlapping clusters between
healthy and MM cells (Fig 4b). These non-overlapping clusters are replicated in t-SNEs con-
structed from forty genes selected using both the random sampling strategy (Fig 4c) as well as the
’balanced’ cell sampling strategy (Fig 4d).
We analyzed the function of the genes identified by the ASFS method and saw that most regulate
housekeeping functions, suggesting that global shifts in translation and motility are disrupted in
multiple myeloma patients. Translation associated markers include Eukaryotic Translation Initia-
tion Factor 1 (EIF1), Eukaryotic Translation Elongation Factor 1 Alpha 1 (EEF1A1), and prefoldin
subunit 5 (PFDN5). Motility associated genes include ACTB, putative anti-adhesion molecule
CD52, and actin-sequestering protein TMSB4X.
We also found both known and potentially novel markers of MM within the peripheral blood
immune cells. Our analysis identifies TPT1, which has been previously associated with MM [40].
We also find that RACK1 (also known as GNB2L1), a scaffolding protein that coordinates critical
functions including cell motility, survival and death, is broadly upregulated in peripheral immune
cells from MM patients. Although this gene has been previously associated with myeloma cells
[41], its regulation had not been previously reported in peripherally circulating immune cells. Our
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A.   Min-cell Strategy
B.   Min-complexity Strategy
Figure 4: Gene selection experiment results of healthy-disease classification on MM dataset. Figure A
shows classification results of 150 genes selected using Min-cell strategy with 100 cells per iteration. Figure
B shows only 40 genes selected by min-complexity strategy using 20 cells each iteration. The results are
shown as Figure 2 in accuracy plot, t-SNE, etc.
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ability to discover MM-specific genes within peripheral immune cells suggests a broader utility for
discovering disease-specific genes across many different types of pathologies.
Discussion
In this paper, we have introduced an active feature selection procedure for discovery of minimal
gene sets using single-cell mRNA-seq data. Our procedure was designed to identify minimal gene
sets in large data sets. Our procedure minimizes the total number of cells and genes that must be
analyzed at each iteration. We demonstrate that ASFS is able to identify small gene sets with tends
to hundreds of genes that still enable highly accurate cell-type classification. In future work, we
aim to demonstrate that the gene sets can be applied to create experimental gene targeting panels.
The core components of our framework can be extended to methods other than SVM as well as to
develop strategies to improve the on-line acquisition of single-cell data.
Data Availability
The PBMC Single-cell RNA-seq data have been deposited in the Short Read Archive under acces-
sion number SRP073767 by the authors of [13]. Data are also available at http://support.
10xgenomics.com/single-cell/datasets.
The original Tabula Muris dataset is available at https://figshare.com/projects/Tabula_
Muris_Transcriptomic_characterization_of_20_organs_and_tissues_from_
Mus_musculus_at_single_cell_resolution/27733.
The original multiple myeloma PBMC dataset, containing 2 healthy donors and 4 multiple myeloma
donors, is available at https://figshare.com/articles/dataset/PopAlign_Data/
11837097/3.
Code Availability
The example source codes including algorithm and preprocessing codes are publicly available on
GitHub at (https://github.com/xqchen/Active-feature-selection-in-single-cell-mRNA-seq-data).
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